Symbol="IKT"
AssetType="Common Stock"
Name="Inhibikase TherapeuticsÂ Inc"
Description="Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia."
CIK="1750149"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="14469000"
EBITDA="-18121884"
PERatio="None"
PEGRatio="None"
BookValue="4.892"
DividendPerShare="0"
DividendYield="0"
EPS="-3.99"
RevenuePerShareTTM="0.033"
ProfitMargin="0"
OperatingMarginTTM="-128.25"
ReturnOnAssetsTTM="-0.342"
ReturnOnEquityTTM="-0.603"
RevenueTTM="141930"
GrossProfitTTM="-8258499"
DilutedEPSTTM="-3.99"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.402"
AnalystTargetPrice="27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="219.63"
PriceToBookRatio="0.492"
EVToRevenue="2.748"
EVToEBITDA="0.733"
Beta="0.826"
num_52WeekHigh="7.26"
num_52WeekLow="2.6"
num_50DayMovingAverage="3.619"
num_200DayMovingAverage="3.873"
SharesOutstanding="5300000"
DividendDate="None"
ExDividendDate="None"
symbol="IKT"
open="2.68"
high="2.81"
low="2.50"
price="2.64"
volume="42509.00"
latest_trading_day="2023-07-24"
previous_close="2.73"
change="-0.09"
change_percent="-3.2967%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="72"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="28"
Volume_recent_avg="218591"
Change_recent_avg="-0.01"
Delta_recent_avg="0.11"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-0.89"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="28"
Aroon_momentum_negative="72"
image_negative_thumbnail_id_1="131"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0045.jpeg"
image_negative_thumbnail_id_2="1086"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0119.jpeg"
image_neutral_thumbnail_id_1="579"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0020.jpeg"
image_neutral_thumbnail_id_2="554"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0045.jpeg"
image_positive_thumbnail_id_1="976"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0138.jpeg"
image_positive_thumbnail_id_2="954"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0116.jpeg"
image_professor_thumbnail_id_1="1194"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
image_professor_thumbnail_id_2="1204"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0038.jpeg"
